[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11201704660YA - Use of markers including filamin a in the diagnosis and treatment of prostate cancer - Google Patents

Use of markers including filamin a in the diagnosis and treatment of prostate cancer

Info

Publication number
SG11201704660YA
SG11201704660YA SG11201704660YA SG11201704660YA SG11201704660YA SG 11201704660Y A SG11201704660Y A SG 11201704660YA SG 11201704660Y A SG11201704660Y A SG 11201704660YA SG 11201704660Y A SG11201704660Y A SG 11201704660YA SG 11201704660Y A SG11201704660Y A SG 11201704660YA
Authority
SG
Singapore
Prior art keywords
diagnosis
treatment
prostate cancer
markers including
filamin
Prior art date
Application number
SG11201704660YA
Inventor
Niven Rajin Narain
Vivek K Vishnudas
Rangaprasad Sarangarajan
Viatcheslav R Akmaev
Original Assignee
Berg Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berg Llc filed Critical Berg Llc
Publication of SG11201704660YA publication Critical patent/SG11201704660YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4742—Keratin; Cytokeratin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
SG11201704660YA 2014-12-08 2015-12-08 Use of markers including filamin a in the diagnosis and treatment of prostate cancer SG11201704660YA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462088931P 2014-12-08 2014-12-08
US201562134956P 2015-03-18 2015-03-18
US201562148294P 2015-04-16 2015-04-16
PCT/US2015/064530 WO2016094425A1 (en) 2014-12-08 2015-12-08 Use of markers including filamin a in the diagnosis and treatment of prostate cancer

Publications (1)

Publication Number Publication Date
SG11201704660YA true SG11201704660YA (en) 2017-07-28

Family

ID=56108067

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201704660YA SG11201704660YA (en) 2014-12-08 2015-12-08 Use of markers including filamin a in the diagnosis and treatment of prostate cancer
SG10202012249YA SG10202012249YA (en) 2014-12-08 2015-12-08 Use of markers including filamin a in the diagnosis and treatment of prostate cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202012249YA SG10202012249YA (en) 2014-12-08 2015-12-08 Use of markers including filamin a in the diagnosis and treatment of prostate cancer

Country Status (10)

Country Link
US (2) US10539566B2 (en)
EP (2) EP3230314B1 (en)
JP (1) JP6759229B2 (en)
KR (1) KR102657306B1 (en)
CN (1) CN107428821B (en)
AU (1) AU2015360694B2 (en)
CA (1) CA2970143A1 (en)
IL (1) IL252766B (en)
SG (2) SG11201704660YA (en)
WO (1) WO2016094425A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016145331A1 (en) * 2015-03-12 2016-09-15 Thermo Finnigan Llc Methods for data-dependent mass spectrometry of mixed biomolecular analytes
WO2016164857A1 (en) * 2015-04-10 2016-10-13 President And Fellows Of Harvard College Methods and devices for live cell imaging analysis
EP3490677A4 (en) * 2016-07-07 2020-05-13 Berg LLC Lipid, protein, and metabolite markers for the diagnosis and treatment of prostate cancer
CN110139656A (en) 2016-08-05 2019-08-16 纽约州州立大学研究基金会 The Keratin 17 of biomarker as bladder cancer
US10759850B2 (en) 2016-11-01 2020-09-01 Berg Llc Filamin A binding proteins and uses thereof
WO2018085441A1 (en) * 2016-11-01 2018-05-11 Berg Llc Filamin b binding proteins and uses thereof
WO2018189292A1 (en) * 2017-04-13 2018-10-18 Institut National De La Sante Et De La Recherche Medicale Biomarkers of castration-resistant prostatic cells
WO2019226347A1 (en) * 2018-05-24 2019-11-28 Sigma-Aldrich Co. Llc Quantitative analysis of proteins
CN108624691A (en) * 2018-06-22 2018-10-09 杭州西合精准医疗科技有限公司 A kind of marker and its application for judging prostatic disorders
EP3821031A4 (en) * 2018-07-12 2022-07-20 Berg LLC Methods for differentiating benign prostatic hyperplasia from prostate cancer
JP7442769B2 (en) 2018-10-09 2024-03-05 アイベックス バイオサイエンシーズ， インコーポレイテッド Antibodies against filamin A and their therapeutic uses
US20210080466A1 (en) * 2019-06-26 2021-03-18 Berg Llc Markers for the diagnosis of prostate cancer
US11042980B1 (en) * 2020-01-02 2021-06-22 Robert Edwin Douglas Method and apparatus for using quantative and qualitative data from medical imaging examinations for precise dosing regimen
CN114134223B (en) * 2021-12-02 2022-10-11 青岛市中心血站 Blood detection kit for hepatitis C virus-related liver fibrosis
CN114155956B (en) * 2021-12-02 2022-09-20 首都医科大学附属北京地坛医院 System and method for predicting blood vessel invasion probability of primary liver cancer patient incapable of being resected by surgery
CN114882996B (en) * 2022-03-17 2023-04-07 深圳大学 Hepatocellular carcinoma CK19 and MVI prediction method based on multitask learning
CN117843753A (en) * 2022-10-04 2024-04-09 中国医学科学院药物研究所 Keratin YK93-2, preparation method, pharmaceutical composition and application thereof

Family Cites Families (197)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4786600A (en) 1984-05-25 1988-11-22 The Trustees Of Columbia University In The City Of New York Autocatalytic replication of recombinant RNA
US4883750A (en) 1984-12-13 1989-11-28 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US6040166A (en) 1985-03-28 2000-03-21 Roche Molecular Systems, Inc. Kits for amplifying and detecting nucleic acid sequences, including a probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
AU622104B2 (en) 1987-03-11 1992-04-02 Sangtec Molecular Diagnostics Ab Method of assaying of nucleic acids, a reagent combination and kit therefore
IL86724A (en) 1987-06-19 1995-01-24 Siska Diagnostics Inc Method and kits for the amplification and detection of nucleic acid sequences
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
AU622426B2 (en) 1987-12-11 1992-04-09 Abbott Laboratories Assay using template-dependent nucleic acid probe reorganization
EP0359789B1 (en) 1988-01-21 1993-08-04 Genentech, Inc. Amplification and detection of nucleic acid sequences
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8822228D0 (en) 1988-09-21 1988-10-26 Southern E M Support-bound oligonucleotides
US4932207A (en) 1988-12-28 1990-06-12 Sundstrand Corporation Segmented seal plate for a turbine engine
US5527681A (en) 1989-06-07 1996-06-18 Affymax Technologies N.V. Immobilized molecular synthesis of systematically substituted compounds
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5242974A (en) 1991-11-22 1993-09-07 Affymax Technologies N.V. Polymer reversal on solid surfaces
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
DE3924454A1 (en) 1989-07-24 1991-02-07 Cornelis P Prof Dr Hollenberg THE APPLICATION OF DNA AND DNA TECHNOLOGY FOR THE CONSTRUCTION OF NETWORKS FOR USE IN CHIP CONSTRUCTION AND CHIP PRODUCTION (DNA CHIPS)
DE3938907C2 (en) 1989-11-24 1999-11-04 Dade Behring Marburg Gmbh Means for storing and suspending cells, in particular erythrocytes
DE3942999C2 (en) 1989-12-27 1997-12-18 Progen Biotechnik Gmbh Procedure for the detection of malignant diseases
IL103674A0 (en) 1991-11-19 1993-04-04 Houston Advanced Res Center Method and apparatus for molecule detection
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
ES2227512T3 (en) 1991-12-02 2005-04-01 Medical Research Council PRODUCTION OF ANTIBODIES AGAINST SELF-ANTIGENS FROM REPERTORIES OF ANTIBODY SEGMENTS FIXED IN A PHOTO.
AU669353B2 (en) 1991-12-24 1996-06-06 Isis Pharmaceuticals, Inc. Gapped 2' modified oligonucleotides
DE4208422A1 (en) 1992-03-16 1993-09-30 Boehringer Mannheim Gmbh Method for the detection of micrometastases of ectodermal or endodermal tumors
WO1994009156A1 (en) 1992-10-08 1994-04-28 The Regents Of The University Of California Pcr assays to determine the presence and concentration of a target
US5554501A (en) 1992-10-29 1996-09-10 Beckman Instruments, Inc. Biopolymer synthesis using surface activated biaxially oriented polypropylene
US5422252A (en) 1993-06-04 1995-06-06 Becton, Dickinson And Company Simultaneous amplification of multiple targets
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
EP0705271B1 (en) 1993-06-25 2002-11-13 Affymetrix, Inc. (a Delaware Corporation) Hybridization and sequencing of nucleic acids
US5472672A (en) 1993-10-22 1995-12-05 The Board Of Trustees Of The Leland Stanford Junior University Apparatus and method for polymer synthesis using arrays
US6045996A (en) 1993-10-26 2000-04-04 Affymetrix, Inc. Hybridization assays on oligonucleotide arrays
US5429807A (en) 1993-10-28 1995-07-04 Beckman Instruments, Inc. Method and apparatus for creating biopolymer arrays on a solid support surface
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
AU687535B2 (en) 1994-03-16 1998-02-26 Gen-Probe Incorporated Isothermal strand displacement nucleic acid amplification
WO1995032305A1 (en) 1994-05-19 1995-11-30 Dako A/S Pna probes for detection of neisseria gonorrhoeae and chlamydia trachomatis
US5571639A (en) 1994-05-24 1996-11-05 Affymax Technologies N.V. Computer-aided engineering system for design of sequence arrays and lithographic masks
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5599695A (en) 1995-02-27 1997-02-04 Affymetrix, Inc. Printing molecular library arrays using deprotection agents solely in the vapor phase
US5624711A (en) 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
WO1997008320A1 (en) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
US5658734A (en) 1995-10-17 1997-08-19 International Business Machines Corporation Process for synthesizing chemical compounds
CA2250118C (en) 1996-03-26 2009-09-29 Michael S. Kopreski Method enabling use of extracellular rna extracted from plasma or serum to detect, monitor or evaluate cancer
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
EP0912767B1 (en) 1996-07-16 2006-09-13 Gen-Probe Incorporated Methods for detecting and amplifying nucleic acid sequences using modified oligonucleotides having increased target specific tm
US6207380B1 (en) 1997-09-15 2001-03-27 Abbott Laboratories Reagents and methods useful for detecting diseases of the urinary tract
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
US6130101A (en) 1997-09-23 2000-10-10 Molecular Probes, Inc. Sulfonated xanthene derivatives
US6124120A (en) 1997-10-08 2000-09-26 Yale University Multiple displacement amplification
US6218114B1 (en) 1998-03-27 2001-04-17 Academia Sinica Methods for detecting differentially expressed genes
US6004755A (en) 1998-04-07 1999-12-21 Incyte Pharmaceuticals, Inc. Quantitative microarray hybridizaton assays
US6218122B1 (en) 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
JP2002527489A (en) 1998-10-22 2002-08-27 キュラゲン コーポレイション Predictive and therapeutic genes and proteins for kidney and related diseases
CA2702148C (en) 1999-01-06 2014-03-04 Genenews Inc. Method of profiling gene expression in a human subject having an infectious disease
US8410248B2 (en) 1999-03-12 2013-04-02 Human Genome Sciences Inc. HWBAO62 polypeptides
US7368527B2 (en) 1999-03-12 2008-05-06 Human Genome Sciences, Inc. HADDE71 polypeptides
US6271002B1 (en) 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
US6607885B1 (en) 1999-10-15 2003-08-19 E. I. Du Pont De Nemours And Company Method for high-density microarray medicated gene expression profiling
US6448086B1 (en) 2000-01-18 2002-09-10 Diagnostic Systems Laboratories, Inc. Insulin-like growth factor system and cancer
CA2404431C (en) 2000-03-27 2011-06-07 Thomas Jefferson University Guanylyl cyclase c in the detection of stomach and esophageal cancers
WO2002014500A2 (en) 2000-08-16 2002-02-21 Chiron Corporation Human genes and gene expression products
EP1322710B2 (en) 2000-09-29 2015-02-18 Life Technologies Corporation Modified carbocyanine dyes and their conjugates
WO2002060317A2 (en) 2001-01-30 2002-08-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of pancreatic cancer
CA2439854A1 (en) 2001-03-01 2002-09-12 Epigenomics Ag Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylatoin status of the genes
EP2799555B1 (en) 2002-03-13 2017-02-22 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
US20040029151A1 (en) 2002-04-09 2004-02-12 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
US20050272052A1 (en) 2002-04-09 2005-12-08 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
ATE516365T1 (en) 2002-05-21 2011-07-15 Sysmex Corp NUCLEIC ACID AMPLIFICATION PRIMER FOR DETECTING CYTOKERATINS AND EXAMINATION METHODS USING THE PRIMERS
US20070042945A1 (en) 2002-09-25 2007-02-22 Genentech, Inc. Nouvelles compositions et methods de traitement du psoriasis
AU2003277016A1 (en) 2002-09-26 2004-05-04 Atomix, Llc Roto-dynamic fluidic system
US20050259483A1 (en) 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Genes and polypeptides relating to prostate cancers
US6974874B2 (en) 2002-10-31 2005-12-13 Bayer Materialscience Llc Reduction of monomer content and stabilization of polyaziridines
US20040109863A1 (en) 2002-12-04 2004-06-10 Peter Emtage Methods of therapy and diagnosis using targeting of cells that express Ly-9
DE10259703A1 (en) 2002-12-19 2004-07-08 Ivonex Gmbh separation process
AU2003299818A1 (en) 2002-12-20 2004-07-22 Applera Corporation Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
US20070104688A1 (en) 2003-02-13 2007-05-10 City Of Hope Small interfering RNA mediated transcriptional gene silencing in mammalian cells
WO2004076614A2 (en) 2003-02-27 2004-09-10 Bernd Hinzmann Human nucleic acid sequences obtained from prostatic carcinomas
WO2004085621A2 (en) 2003-03-20 2004-10-07 Dana-Farber Cancer Institute, Inc. Gene expression in breast cancer
WO2004111603A2 (en) 2003-05-28 2004-12-23 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
JP2007516693A (en) 2003-06-09 2007-06-28 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン Compositions and methods for the treatment and diagnosis of cancer
WO2005007830A2 (en) 2003-07-14 2005-01-27 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
US20070105114A1 (en) 2003-07-29 2007-05-10 Martha Li Biomarkers of cyclin-dependent kinase modulation
EP1892306A3 (en) 2003-10-06 2008-06-11 Bayer HealthCare AG Methods and kits for investigating cancer
ITPD20030264A1 (en) 2003-10-30 2005-04-30 Xeptagen Spa HIGHLY SPECIFIC DIAGNOSIS METHOD FOR NEOPLASIA
CN1743849A (en) 2004-09-03 2006-03-08 上海透景生命科技有限公司 Multi tumour tag parallel detecting method and kit
US20060057127A1 (en) 2004-09-10 2006-03-16 Pocheng Liu Cytokine-expressing cellular vaccines for treatment of prostate cancer
US20060063214A1 (en) * 2004-09-17 2006-03-23 Ozge Alper Methods and compositions for diagnosing neoplastic disease
JP2008518610A (en) 2004-11-03 2008-06-05 アルマック ダイアグノスティックス リミテッド Transcriptome microarray technique and method of using the same
US7666595B2 (en) 2005-02-25 2010-02-23 The Brigham And Women's Hospital, Inc. Biomarkers for predicting prostate cancer progression
US8383357B2 (en) 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US8093011B2 (en) 2005-03-16 2012-01-10 Haley John D Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US7608413B1 (en) 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
JP5190654B2 (en) 2005-03-31 2013-04-24 国立大学法人広島大学 Method for identifying mesenchymal stem cells using molecular markers and use thereof
CA2608359A1 (en) 2005-05-13 2006-11-23 Duke University Gene expression signatures for oncogenic pathway deregulation
WO2006127861A2 (en) 2005-05-25 2006-11-30 Expression Pathology, Inc. Diagnosis of diseases and conditions by analysis of histopathologically processed biological samples using liquid tissue preparations
US7906301B2 (en) 2005-05-25 2011-03-15 Expression Pathology, Inc. Multiplex method for increased proteomic coverage from histopathologically processed biological samples, tissues cells
JP2008546387A (en) 2005-06-13 2008-12-25 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Compositions and methods for treating and diagnosing cancer
WO2006135886A2 (en) 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1734118A1 (en) 2005-06-15 2006-12-20 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Identification of JAK/STAT pathway modulating genes by genome wide RNAi screening
US7842466B1 (en) 2005-09-16 2010-11-30 Celera Corporation Colon disease targets and uses thereof
WO2007047796A2 (en) 2005-10-17 2007-04-26 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
US20070220621A1 (en) 2005-10-31 2007-09-20 Clarke Michael F Genetic characterization and prognostic significance of cancer stem cells in cancer
WO2007119111A2 (en) 2005-11-10 2007-10-25 Aurelium Biopharma Inc. Tissue diagnostics for ovarian cancer
EP1963860A1 (en) 2005-12-19 2008-09-03 University of Hull Cancer screening test
US20070231822A1 (en) 2006-02-28 2007-10-04 Michael Mitas Methods for the detection and treatment of cancer
JP4968577B2 (en) 2006-04-11 2012-07-04 エフ．ホフマン−ラ ロシュ アーゲー Rapid measurement method of cytokeratin 19 (CK19) mRNA, and primer and probe therefor
US20080003624A1 (en) 2006-06-13 2008-01-03 Sysmex Corporation Cancer metastasis determination method
US7901902B2 (en) 2006-07-27 2011-03-08 Biosante Pharmaceuticals, Inc. Methods and compositions for identifying a cellular immune response against prostate cancer
WO2008021290A2 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
US8642349B1 (en) 2006-08-11 2014-02-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Artificial neural network proteomic tumor classification
US8748108B2 (en) 2006-09-05 2014-06-10 Abbvie Inc. Biomarkers for identifying patient classes
ATE522813T1 (en) 2006-09-07 2011-09-15 Universitaetsklinikum Hamburg METHOD FOR DETECTING CARCINOMATOUS EPITHELIAL CELLS USING RELEASED CYTOKERATINS AS A MARKER FOR THESE CELLS
EP2094719A4 (en) 2006-12-19 2010-01-06 Genego Inc Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom
EP1972639A3 (en) 2007-03-07 2008-12-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
WO2008121307A2 (en) 2007-03-28 2008-10-09 Cell Genesys, Inc. Methods and compositions for identifying prostate cancer or a humoral immune response against prostate cancer
EP2145021A2 (en) 2007-05-17 2010-01-20 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
US20090221004A1 (en) 2007-06-01 2009-09-03 Anita Lim Hong Caspase-cleavage anti-keratin antibodies for detection of apoptosis
US8889361B2 (en) 2007-09-19 2014-11-18 The Research Foundation For The State University Of New York Gene expression signatures in enriched tumor cell samples
CA2694356A1 (en) 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20090105167A1 (en) 2007-10-19 2009-04-23 Duke University Predicting responsiveness to cancer therapeutics
CA2708173C (en) 2007-12-04 2016-02-02 Alnylam Pharmaceuticals, Inc. Targeting lipids
CA2706115A1 (en) 2007-12-10 2009-06-18 F. Hoffmann-La Roche Ag Seprase as a marker for cancer
SG190670A1 (en) 2008-02-01 2013-06-28 Gen Hospital Corp Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions
US8008032B2 (en) 2008-02-25 2011-08-30 Cellective Dx Corporation Tagged ligands for enrichment of rare analytes from a mixed sample
MX2011000451A (en) 2008-07-16 2011-10-12 Dana Farber Cancer Inst Inc Signatures and pcdeterminants associated with prostate cancer and methods of use thereof.
WO2010011642A2 (en) 2008-07-21 2010-01-28 The Trustees Of The University Of Pennsylvania Methods and compositions using splicing regulatory proteins involved in tumor suppression
EP2177615A1 (en) 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
US8312249B1 (en) 2008-10-10 2012-11-13 Apple Inc. Dynamic trampoline and structured code generation in a signed code environment
IT1391619B1 (en) 2008-11-04 2012-01-11 Silicon Biosystems Spa METHOD FOR THE IDENTIFICATION, SELECTION AND ANALYSIS OF TUMOR CELLS
CN102209899B (en) 2008-11-12 2014-05-07 霍夫曼-拉罗奇有限公司 Pacap as a marker for cancer
CN102308212A (en) 2008-12-04 2012-01-04 加利福尼亚大学董事会 Materials and methods for determining diagnosis and prognosis of prostate cancer
JP5368579B2 (en) 2008-12-22 2013-12-18 エフ．ホフマン−ラ ロシュ アーゲー ARMET as a marker for cancer
EP2400990A2 (en) 2009-02-26 2012-01-04 OSI Pharmaceuticals, LLC In situ methods for monitoring the emt status of tumor cells in vivo
JP2012100536A (en) 2009-03-02 2012-05-31 Genescience Co Ltd Genetic testing method for cancer by analysis of expression of cancer-relating gene utilizing monocyte contained in blood sample
WO2010099918A1 (en) 2009-03-06 2010-09-10 Klaus Tschira Stiftung Ggmbh Pharmaceutical composition and method for identifying a cancerous and/or an inflammatory disease in a patient
EP2421900A1 (en) 2009-04-24 2012-02-29 Alper Biotech, Llc Monoclonal antibodies against pcbp-1 antigens, and uses therefor
US10815517B2 (en) 2009-04-28 2020-10-27 Roche Diagnostics Operations, Inc. Use of DPPIV/seprase as a marker for cancer
JP5892794B2 (en) 2009-10-02 2016-03-23 学校法人 久留米大学 Method for predicting therapeutic effect and / or prognosis after immunotherapy for cancer patients, and gene set and kit used for the method
EP2309262A1 (en) * 2009-10-06 2011-04-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for quantifying biomolecules
US9456558B2 (en) 2009-10-29 2016-10-04 King Kutter, Inc. Stump cutter
EP2335838B1 (en) 2009-12-18 2012-09-26 Deutsche Post AG Sorting system and method using a portable device
US20130095503A1 (en) 2010-01-05 2013-04-18 University Of Cincinnati Serum spla2-iia as diagnosis marker for prostate and lung cancer
US20110177525A1 (en) 2010-01-19 2011-07-21 Predictive Biosciences, Inc. Antibodies and methods of diagnosing diseases
FR2957821B1 (en) 2010-03-24 2014-08-29 Inst Francais Du Petrole NEW AREA OF CATALYST REGENERATION DIVIDED IN SECTORS FOR REGENERATIVE CATALYTIC UNITS
KR20130043104A (en) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 Circulating biomarkers for disease
US8664472B2 (en) 2010-04-28 2014-03-04 Sesaco Corporation Pygmy sesame plants for mechanical harvesting
EP2390665A1 (en) 2010-05-27 2011-11-30 Atlas Antibodies AB Prostate cancer biomarkers
WO2012006634A2 (en) 2010-07-09 2012-01-12 The Board Of Trustees Of The University Of Illiniois Prostate specific antigen (psa) peptide therapy
US8557777B2 (en) 2010-07-09 2013-10-15 The Board Of Trustees Of The University Of Illinois Methods for treating cancer using prostate specific antigen and tumor endothelial marker peptides
CA2807209C (en) 2010-08-16 2019-09-17 Mount Sinai Hospital Markers of the male urogenital tract
AU2011291599B2 (en) 2010-08-18 2015-09-10 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for disease
US20140045915A1 (en) 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
WO2012031374A1 (en) 2010-09-09 2012-03-15 北京同为时代生物技术有限公司 Blood markers for diagnosing epithelium derived cancers and monoclonal antibodies thereof
AU2011302152B2 (en) 2010-09-15 2015-06-11 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
EP2649445B1 (en) 2010-12-06 2015-05-06 THD S.p.A. Method for the diagnosis of a carcinoma
US20130288233A1 (en) 2010-12-24 2013-10-31 Map Diagnostics Pty Ltd. Selective Reaction Monitoring (SRM) Derived Protein Profiles for Cancer and other Pathologic Entities
ES2545515T3 (en) 2011-01-28 2015-09-11 F. Hoffmann-La Roche Ag Combinatorial biomarkers for clinical applications in the management of lung cancer patients
WO2012116248A1 (en) 2011-02-24 2012-08-30 Massachusetts Institute Of Technology ALTERNATIVELY SPLICED mRNA ISOFORMS AS PROGNOSTIC INDICATORS FOR METASTATIC CANCER
MY164530A (en) 2011-03-02 2017-12-29 Berg Llc Interrogatory cell-based assays and uses thereof
KR101320633B1 (en) 2011-05-25 2013-10-30 엠앤디 (주) Method of providing information for diagnosis of cancer using quantitative realtime PCR and diagnostic kit comprising thereof
WO2012135397A2 (en) 2011-03-29 2012-10-04 Lisanti Michael P Lactate-and ketones-induced gene signatures and use the same for diagnosing disease and predicting clinical outcome
CN103874706B (en) * 2011-04-28 2016-06-08 贝勒医学院 The chimeric RNA of the regeneration as biomarker in human prostate cancer's enrichment
WO2012174256A2 (en) 2011-06-17 2012-12-20 The Regents Of The University Of Michigan Dna methylation profiles in cancer
EP2551673B1 (en) 2011-07-26 2016-01-20 Universidad de Salamanca Methods for the detection of cancer infiltration of the central nervous system
CA2844671A1 (en) 2011-08-08 2013-02-14 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarker compositions and methods
US10226238B2 (en) 2011-09-12 2019-03-12 Creatics Llc Non-invasive methods of detecting target molecules
AU2013229762A1 (en) 2012-03-09 2014-09-25 Caris Life Sciences Switzerland Holdings Gmbh Biomarker compositions and methods
ES2875535T3 (en) 2012-03-29 2021-11-10 Biogen Ma Inc Biomarkers for use in Integrin Therapy Applications
US20130317083A1 (en) 2012-05-04 2013-11-28 Thomas Jefferson University Non-coding transcripts for determination of cellular states
WO2013166676A1 (en) 2012-05-09 2013-11-14 华为技术有限公司 Method and device for data transmission
WO2013173476A1 (en) * 2012-05-15 2013-11-21 Predictive Biosciences, Inc. Detection of cancer
US20140038838A1 (en) * 2012-06-27 2014-02-06 Niven Rajin Narain Use of markers in the diagnosis and treatment of prostate cancer
TWI468519B (en) 2012-09-05 2015-01-11 Univ China Medical Methods of detecting squamous cell carcinoma in vitro
EP2895864B1 (en) 2012-09-17 2021-03-10 AIT Austrian Institute of Technology GmbH Colon cancer diagnostic method and means
US10054596B2 (en) * 2013-01-22 2018-08-21 Neoproteomics Ab Platelet biomarkers in cancer diagnosis
US9201061B2 (en) 2013-02-26 2015-12-01 Industry-University Cooperation Foundation Hanyang University KRT19 stabilizing HER2 and use thereof
US20160033511A1 (en) 2013-03-13 2016-02-04 Creatics Llc Methods and compositions for detecting pancreatic cancer
US20140296096A1 (en) * 2013-03-27 2014-10-02 Oslo Universitetssykehus Hf Prostate cancer markers and uses thereof
SE538211C2 (en) 2013-04-05 2016-04-05 Idl Biotech Ab Method for detecting cytokeratin 8, 18 and / or 19 and / or soluble fragments thereof
US20150079590A1 (en) 2013-09-18 2015-03-19 Beth Israel Deaconess Medical Center, Inc. Characterization and analysis of the composition and dynamics of the mammalian riboproteome
EP3047270A4 (en) 2013-09-20 2017-07-19 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of appendicitis and differentiation of causes of abdominal pain

Also Published As

Publication number Publication date
WO2016094425A1 (en) 2016-06-16
KR20170092671A (en) 2017-08-11
AU2015360694B2 (en) 2021-10-14
US10539566B2 (en) 2020-01-21
CA2970143A1 (en) 2016-06-16
IL252766B (en) 2021-07-29
AU2015360694A1 (en) 2017-06-29
EP3230314A1 (en) 2017-10-18
IL252766A0 (en) 2017-08-31
KR102657306B1 (en) 2024-04-12
CN107428821B (en) 2022-06-24
JP6759229B2 (en) 2020-09-23
EP4242329A2 (en) 2023-09-13
US20160258958A1 (en) 2016-09-08
EP3230314B1 (en) 2023-05-03
US20200333344A1 (en) 2020-10-22
EP4242329A3 (en) 2023-10-25
CN107428821A (en) 2017-12-01
JP2018506045A (en) 2018-03-01
EP3230314A4 (en) 2018-06-06
SG10202012249YA (en) 2021-01-28

Similar Documents

Publication Publication Date Title
IL252766A0 (en) Use of markers including filamin a in the diagnosis and treatment of prostate cancer
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
GB201403093D0 (en) Therapeutic compounds and their use
IL276733A (en) Use of eribulin in the treatment of cancer
IL251630A0 (en) Combination therapy for use in cancer therapy
HRP20190888T8 (en) Igf-1r antibody-drug-conjugate and its use for the treatment of cancer
SG11201701035SA (en) Cancer diagnosis and therapy
HK1209792A1 (en) Use of markers in the diagnosis and treatment of prostate cancer
IL249741A0 (en) Identification of cancer stem cells markers and use of same for diagnosis and treatment
GB201409363D0 (en) Skin cancer treatment
PL3258931T3 (en) Use of cabazitaxel in the treatment of prostate cancer
IL269121A (en) Usl-311 for use in the treatment of cancer
IL273054A (en) Abx196 for use in the treatment of bladder cancer
IL251825B1 (en) Cancer and skin lesion treatment
GB201612794D0 (en) Therapeutic use of diethanololeamide in prostate cancer treatment
GB201411111D0 (en) bis-Pyridazine compounds and their use in treating cancer
GB201410387D0 (en) Compounds and their therapeutic use
GB201409978D0 (en) Novel compounds and their use in therapy
GB201403496D0 (en) Compounds and their therapeutic use